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Objective: To present epidemiologic and clinical data
from the Australasian Epidermolysis Bullosa (EB) Reg-
istry, the first orphan disease registry in Australia.
Design: Observational study (cross-sectional and lon-
gitudinal).
Setting: Australian private dermatology practice, inpa-
tient ward, and outpatient clinic.
Patients: Systematic case finding of patientswith EB sim-
plex, junctional EB (JEB), and dystrophic EB and data
collectionwere performed throughout Australia andNew
Zealand from January 1, 2006, through December 31,
2008. Patients were consecutively enrolled in the study
after clinical assessment and laboratory diagnosis. Medi-
cal records were retrospectively examined, and physi-
cians involved in EB care were contacted to obtain pa-
tient history. A Herlitz JEB case series was prepared from
registry data.
Main Outcome Measures: Demographics and prog-
nosis of patients with Herlitz JEB.
Results:A total of 259 patientswere enrolled in the study:
139 with EBS, 91 with dystrophic EB, 28 with JEB, and
1 with Kindler syndrome. Most enrollees were Austra-
lian citizens (n=243), with an Australian prevalence rate
of 10.3 cases per million. The age range in the registry
was birth to 99 years, with amean andmedian age of 24.1
and 18.0 years, respectively. Ages were similar in pa-
tients with EBS and dominant dystrophic EB but were
markedly lower in patients with JEB. Patients with Her-
litz JEB (n=10) had the highest morbidity andmortality
rates, with amean age at death of 6.8months. Sepsis, fail-
ure to thrive, and tracheolaryngeal complications were
the leading causes of death.
Conclusions:TheAustralasian EB registry is the first reg-
istry in Australia and New Zealand to provide original
data on age, sex, ethnicity, and geographical and dis-
ease subtype distribution. The Australasian Herlitz JEB
cohort witnessed a high infant mortality rate and poor
prognosis overall.
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E PIDERMOLYSIS BULLOSA (EB)refers to a group of geno-dermatoses characterized bythe excessive susceptibilityof the skin to separate from
underlying tissues afterminimalmechani-
cal trauma. Three major types of EB ex-
ist, distinguished by the ultrastructural
level of blister formation: EB simplex
(EBS), junctional EB (JEB), and dystro-
phic EB (DEB), which, respectively, de-
scribe epidermolytic, lucidolytic, and der-
molytic patterns of blistering.1 In addition,
there is a fourth type, Kindler syndrome,
which features blistering at various lev-
els. Further distinction can be made be-
tween dominant DEB and recessive DEB
(RDEB) based on the greater clinical se-
verity of recessive subtypes.
Although several registries for EB ex-
ist overseas, no epidemiologic or clinical
data have been published for the Austra-
lasian cohort of patients living with EB.
Such data have become recently available
with the emergence of the Australasian
Epidermolysis Bullosa Registry (AEBR),
permitting the contribution of Austra-
lia’s experience of EB to the medical lit-
erature. This is the first orphan disease reg-
istry to be established in Australia.
METHODS
The AEBRwas developed during 2005 and es-
tablished on November 8, 2006, at St George
Hospital in Sydney, subsequent to gaining eth-
ics approval from the SouthEastern Sydney and
Illawarra Human Research Ethics Commit-
tee. Patients were consecutively enrolled in the
registrywithwritten informed consent from the
Sydney Children’s Hospital, St George Hospi-
tal, Dr Murrell’s private dermatology practice,
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The Children’s Hospital at Westmead, The Royal Children’s
Hospital, Mater Children’s Hospital, and the Dystrophic Epi-
dermolysis Bullosa Research Associations of Australia and
New Zealand.
Patient diagnoses were confirmed by a combination of clini-
cal assessment by EB dermatologists, immunofluorescencemap-
ping, and transmission electron microscopy. Recruitment oc-
curred predominantly within Australia; however, a few patients
were recruited from New Zealand (n=16).
Comprehensive data collection was performed at the time of
patient enrollment using a data instrument, with additional data
collection performed on subsequent presentations. The data col-
lection fields used were influenced by research previously per-
formed by the National Epidermolysis Bullosa Registry in the
UnitedStates, locatedatTheUniversityofNorthCarolinaatChapel
Hill and Stanford University.2 Data collection fields included pa-
tient demographics; past and currentmedical history; family his-
tory; diagnostic laboratory studies; areas of blistering or erosion;
tracheolaryngeal complications; gastrointestinal complications;
weight and growth development; hair, teeth, and nail findings;
ocular complications; and genitourinary complications.
Wherever available, preexisting hospital outpatient and in-
patient clinical records along with private dermatologic prac-
tice notes were examined for each patient. Physicians respon-
sible for the care of patients with Herlitz JEB (JEB-H) were
additionally contacted by telephone or electronic mail for fur-
ther clinical information.
Data were then entered into a password-protected data-
base usingMicrosoft Access, version 11.8166.8221 (Microsoft
Corporation, Redmond, Washington) from January 1, 2006,
through December 31, 2008. In January 2009, data sets were
extracted and analyzed using Microsoft Excel and SPSS statis-
tical software, version 16.0.1 (SPSS Inc, Chicago, Illinois). Re-
sults were stratified by major EB type wherever relevant, and a
JEB-H case series was prepared from registry data.
RESULTS
DEMOGRAPHICS
The AEBR contained 259 patients with a confirmed di-
agnosis of EB: 131male and 128 female patients. Of these,
139 (53.7%) had EBS, 91 (35.1%) had DEB, 28 (10.8%)
had JEB, and 1 (.4%) had Kindler syndrome. Further EB
subclassificationswere available for 176 patients, whereas
83 patients had no further subclassification because of
insufficient data (Table 1).
Mostpatients in theAEBRwereAustralian (n=243),with
a small number from New Zealand (n=16). Of the Aus-
tralianpatients, 146were fromthestateofNewSouthWales,
34 fromVictoria, 29 fromQueensland, 23 fromSouthAus-
tralia, 5 from Western Australia, 4 from Tasmania, and 2
from the Australian Capital Territory (Figure 1).
Among the 113 patients who reported their ethnicity
(Table2),mostwerewhite(n=70), followedbyindigenous
Australian (n=11), Chinese (n=4), Arabic (n=4), Italian
(n=3), and Lebanese (n=3). There were a small number
from other ethnicities, including Afghani, Maltese, Indo-
nesian,Turkish,African,Bulgarian,Czech,Danish,Greek,
Iraqi, Portuguese, Serbian, Tongan, and Ukrainian.
The patients’ ages in the registry (n=247) ranged from
birth through99 years,with amean age of 24.1 years and a
medianageof18.0years.Thepatients’ages, stratifiedbyma-
jor EB type, are presented in Table 3. The EBS (n=133),
dominantDEB(n=55),RDEB(n=34), andJEB(n=25)pa-
tient cohorts had median ages of 20.0, 18.0, 22.5, and 2.0
years, respectively, and age ranges of birth through 99, 0
through73, 0 through78, and0 through35years. Patients
withnodateofbirthenteredwereexcluded fromtheanaly-
sis (n=11).
THE JEB-H COHORT
Seventeen patients in the registry had died as a result of
EB: patientswith the JEB-H subtype experienced thehigh-
est mortality rates (n=10), followed by patients with se-
vere generalized RDEB (n=4), JEB with pyloric atresia
(n=2), and non-Herlitz JEB (n=1). Most patients with
JEB died during infancy, whereas most patients with se-
vere generalized RDEB died in early adulthood of meta-
static skin cancer. Themean age at death for the patients
Table 1. Patient Diagnoses in the Australasian
Epidermolysis Bullosa Registry
Epidermolysis Bullosa Subtype
No. (%) of Patients
(N=259)a
Epidermolysis bullosa simplex 139 (53.7)
Undetermined subtype 73 (28.2)
Dowling-Meara 27 (10.4)
Weber-Cockayne 17 (6.6)
Koebner 13 (5.0)
Mottled pigmentation 5 (1.9)
Superficialis 4 (1.5)
Dystrophic epidermolysis bullosa 91 (35.2)
Dominant 46 (17.8)
Recessive severe generalized 17 (6.6)
Recessive severe generalized other 17 (6.6)
Undetermined subtype 11 (4.3)
Junctional epidermolysis bullosa 28 (10.8)
Non-Herlitz 13 (5.0)
Herlitz 11 (4.2)
With pyloric atresia 3 (1.2)
Laryngo-onycho-cutaneous syndrome 1 (0.4)
Kindler syndrome 1 (0.4)
aPercentages may not total 100 because of rounding.
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Figure 1. Distribution of Australian and New Zealand patients in the
Australasian Epidermolysis Bullosa Registry. ACT indicates Australian Capital
Territory; NSW, New South Wales; NT, Northern Territory; NZ, New Zealand;
QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; and
WA, Western Australia.
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with severe generalized RDEB was 29.4 years, with an
age range of 23 through 35 years. Table 4 lists the age
at death and recorded causes of death for deceased pa-
tients in the registry.
Of the 11 patients with JEB-H in the registry, 10 had
sufficient recorded data to investigate disease course and
prognosis. All 10 patients diedwithin the first 12.7months
of life, with a mean age at death of 6.8 months, an age
range of 2.0 through12.7months, and an SDof 0.9month.
A major cause of death in the JEB-H cohort was sep-
sis; deepithelized skin resulted in frequent infection for
all infants, with 4 of 10 patients progressing to sepsis and
3 of 10 patients dying from sepsis-related complica-
tions. Staphylococcus aureus, group A Streptococcus, and
Staphylococcus capitiswere isolated from blood cultures
before death. Blister and erosion formation most fre-
quently occurred over the buttocks and perineum in a
diaper pattern of distribution, followed by blistering on
the legs and arms. The frequency of blistering over vari-
ous body parts, recorded on initial and subsequent hos-
pital presentations, is summarized in Table 5.
Malabsorptionwith secondary failure to thrivewas the
secondmajor causeof death in the JEB-Hcohort, affecting
most infants. All JEB-H patients demonstrated a progres-
sivenutritional decline as they advanced through life, fall-
ingwell below the first percentile typically by 3months of
age. Six of 10 patients were recorded to have received
nutritional intervention,with4 receivingnasogastric tube
feeding on at least 1 occasion and 3 receiving gastrostomy
feeding. Oral erosions were noted in 9 patients, whereas
6 demonstrated an iron deficiency pattern of anemia.
Tracheolaryngeal complications were a third major
cause of death, with bullae forming in the tracheolaryn-
geal tract of 7 of 10 infants overall. Of the 10 infants,
5 demonstrated a hoarse cry, 2 developed tracheal struc-
turing, 2 exhibited inspiratory stridor, 2 experiencedmild
respiratory distress, 2 had intermittent apneic episodes,
and 1 received a tracheostomy at 3 months of age.
Table 2. Ethnicity of Patients in the Australasian
Epidermolysis Bullosa Registry
Ethnicity
No. (%) of Patients
(N=259)a
Unreported 146 (56.4)
White 70 (27.0)
Indigenous Australian 11 (4.2)
Arabic 4 (1.5)
Chinese 4 (1.5)
Italian 3 (1.2)
Lebanese 3 (1.2)
Afghani 2 (0.8)
Indonesian 2 (0.8)
Maltese 2 (0.8)
Turkish 2 (0.8)
Others (African, Bulgarian, Czech, Danish, Greek,
Iraqi, Portugese, Serbian, Tongan, Ukrainian)
1 per group
(0.4 each)
aPercentages do not total 100 because of rounding.
Table 3. Patient Age Distribution by Epidermolysis
Bullosa Type
Epidermolysis
Bullosa Type
Mean
Age, y
Median
Age, y
Age Range
(SD), y
EBS (n=133) 26.2 20.0 0-99 (1.8)
DDEB (n=55) 21.8 18.0 0-73 (2.4)
RDEB adjusteda (n=32) 24.5 22.0 0-60 (2.6)
RDEB unadjusted (n=34) 27.6 22.5 0-78 (3.2)
JEB (n=25) 7.9 2.0 0-35 (2.2)
Abbreviations: DDEB, dominant dystrophic epidermolysis bullosa;
EBS, epidermolysis bullosa simplex; JEB, junctional epidermolysis bullosa;
RDEB, recessive dystrophic epidermolysis bullosa.
aTwo patients with RDEB are extreme outliers at ages 76 and 78 years.
Table 4. Causes of Death for Patients in the Australasian
Epidermolysis Bullosa Registry
Epidermolysis
Bullosa Subtype
Age at
Death Cause of Death
JEB with PA 0 mo Renal failure
JEB-H (patient 1) 2 mo Toxic shock
JEB with PA 4 mo Gastrointestinal hemorrhage
JEB-H (patient 2) 5 mo Tracheal strictures
JEB-H (patient 3) 5 mo Sepsis and multisystem organ failure
JEB-H (patient 4) 5 mo Unavailable
JEB-H (patient 5) 5 mo Gastrointestinal hemorrhage
JEB-H (patient 6) 6 mo Malabsorption and prolonged apneic
episodes
JEB-H (patient 7) 7 mo Malabsorption, anemia, and aberrant
electrolytes
JEB-H (patient 8) 8 mo Sepsis and chronic malabsorption
JEB-H (patient 9) 8 mo Unavailable
JEB-H (patient 10) 12 mo Pneumonia within a background of
chronic malabsorption
JEB-nH 15 y Cardiomyopathy
RDEB-SG 23 y Metastatic squamous cell carcinoma
RDEB-SG 35 y Metastatic squamous cell carcinoma
RDEB-SG 30 y Renal failure
RDEB-SG 34 y Metastatic squamous cell carcinoma
Abbreviations: JEB, junctional epidermolysis bullosa; H, Herlitz;
nH, non-Herlitz; PA, pyloric atresia; RDEB, recessive dystrophic
epidermolysis bullosa; SG, severe generalized.
Table 5. Recorded Areas of Blistering in the Herlitz
Junctional Epidermolysis Bullosa Cohort
Area of Blistering
Recorded
Frequency, %
Buttocks and perineum
(diaper distribution)
20
Legs and thighs 18
Arms and forearms 15
Inside mouth 14
Abdomen 10
Fingers 8
Axillae 6
Back 6
Face 6
Neck 6
Feet 6
Trunk 5
Hands 5
Elbows 5
Cornea 2
Scalp 2
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Nail abnormalities alongwithmultiple cutaneous bul-
lae and erosions were a prominent early physical finding
in this cohort, with 6 of 10 patients overall developing nail
dystrophy (n=3), anonychia (n=1), or subungual ero-
sions (n=3)within several daysof birth.Ahoarse cry (n=1)
andhyperkeratosis of thepalms and soles (n=1)were other
manifestations observed during this period. Other com-
plications occurring throughout life include gastroenteri-
tis or frequent diarrhea (n=3), gastroesophageal reflux
(n=3), pneumonia (n=2), corneal ulceration (n=2), and
facial granulation tissue formation observed (n=2).
COMMENT
The AEBR is the first orphan disease registry in Austra-
lia, and since its inception in 2006, it has continued to
increase in size and profile locally. However, the regis-
try has likely only recruited a small proportion of the true
population with EB in Australia. This is thought to be
because of the relatively limited recruitment time, geo-
graphical limitations faced by the registry, and the ex-
pectation that less severe EB subtypes are less likely to
present clinically.
Based in New SouthWales, the registry’s geographical
limitations are readily apparent when examining the con-
siderably higher recruitment rate observed in New South
Wales compared with other states. After adjustments for
population size,3 New South Wales recruited 20.6 pa-
tients with EB per million compared with 14.4, 6.8, and
6.4 per million, respectively, for the next 3 highest states:
South Australia, Queensland, and Victoria. As awareness
of the registry continues to grow in other states and with
the possibility of establishing additional registry operat-
ing sites, this discrepancywill perhaps be addressed in the
foreseeable future.
Another recognized issue is the underrecruitment of pa-
tients with less severe forms of EB, particularly individu-
als with EBS. With the living Australian cohort compris-
ing 125 patients with EBS, 15 with JEB, and 81with DEB,
the prevalence rate based solely on registry cases is 5.8EBS,
0.7 JEB, and 3.8 DEB cases per million (10.3 per million
overall). The rates of EBS, JEB, andDEB in theNew South
Wales population, which provide the most reliable indi-
cator of prevalence based onhigh recruitment in this state,
are 10.5, 2.1, and 8.0 cases per million, respectively.
Although the nationwide prevalence of JEB and DEB
according to AEBR data are fairly consistent with epide-
miologic studies performed overseas,2,4-11 the EBS preva-
lence in Australia is lower than the rates reported inmost
countries (Table 6). The extent of missed EBS recruit-
ment in Australia is evident by a Tasmanian study12 pub-
lished in 1963 describing 83 cases of EBS in 1 extended
family, whereas the AEBR by contrast has only 3 re-
corded cases from Tasmania.
As has been suggested by other studies, underreport-
ing of EBS may result from its milder phenotype provid-
ing insufficient impetus for clinical presentation.2,8 In ad-
dition, because EB is rare theremay be a lack of knowledge
about the disorder, resulting inmissed diagnoses or a re-
duced likelihood of some physicians to refer patients for
further investigation. One study in Scotland8 found that
30% of interviewed patients with EBS or dominant DEB
had never seen a dermatologist, whereas in the experi-
ence of the AEBR investigators, many patients with EBS
had had their conditions misdiagnosed as eczema or had
otherwise regarded their skin disease as normal.
By contrast, it is reasonable to suggest that the AEBR
has enrolled a greater proportion of individuals livingwith
DEB and JEB. These subtypes require a greater use of the
health care system because of their relative severity and,
accordingly, patients with these subtypes are more likely
to have their conditions diagnosed. One of the great suc-
cesses of the AEBR to date relating to this factor has been
the successful lobbying of the Australian federal govern-
ment to provide a dedicated budget to subsidize the costs
of wound dressings for patients with EB and their fami-
lies, demonstrating the practical value of an orphan dis-
ease registry.
The data obtained from the registry suggest that the
AEBR represents a reasonable cross-section of the true
populationwithEB,withessentially equalnumbersofmales
and females and a diverse age range. However, a signifi-
cant rightward skew exists in the patients’ ages overall
(Figure2), indicating that themore severe JEB andDEB
subtypes have prevented individuals from progressing to
Table 6. Recorded Prevalence of Epidermolysis Bullosa
(per Million)
Country EBS JEB DEB
United States2 4.6 0.4 2.4
Croatia4 NA NA 19.2a
Finland5 15.1 0.2 8.8
Japan6 4.0 0.2 3.5
Northern Ireland7 28.0 0.7 3.0
Scotland8 28.6 NA 20.4
Sweden9 NA 8.0 NA
South Africa10 0.8 0.7 1.2
Norway11 24.3 NA 9.3
Australia, AEBR 5.6 0.7 3.9
New South Wales 10.5 2.1 8.0
New Zealand, AEBR 2.9 0.0 1.0
Abbreviations: AEBR, Australasian Epidermolysis Bullosa Registry;
DEB, dystrophic epidermolysis bullosa; EBS, epidermolysis bullosa simplex;
JEB, junctional epidermolysis bullosa; NA, not applicable.
aSevere generalized recessive dystrophic epidermolysis bullosa only.
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Figure 2. Frequency histogram of patient ages in the Australasian
Epidermolysis Bullosa Registry.
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old age or thatmany older individuals have not been iden-
tified by the registry. Although the former may be true, it
ismore likely thatmanyolder individualswithmilder forms
of EB have not yet been recruited into the registry be-
cause their inclusionwould dilute the effect of premature
mortality in the less common subtypes.
Thecomparisonof thepatients’ agesbyEBtype(Table3)
also broadly reflects the clinical severity of the EB types; it
indicates thatmost subtypes ofEBS anddominantDEBare
compatiblewith anormal lifespan,whereasRDEBand JEB
subtypes by contrast are associated with higher morbidity
rates andprematuremortality. This relationship iswell re-
flected in the literature2,13-16 and is furthermore apparent
with the number of deceased patients in the registry who
had had JEB and RDEB (Table 4). Underreporting of EBS
deathsmayhaveoccurredbecause the registry reliesonno-
tification by relatives when patients with milder pheno-
types die in nonhospital environments.
Herlitz JEB was associated with the greatest mortality
rates in theAEBR,with an infantmortality rate higher than
that reported in the United States. The US registry found
that 44.7%of infantswith JEB-Hhad diedwithin their first
year of life13 compared with 9 of 10 infant deaths in the
AEBR. However, the leading causes of death experienced
in the US JEB-H cohort were consistent with those expe-
rienced in the AEBR.
A few explanations may be offered as to why the Aus-
tralasian cohort of JEB-H infants experienced such high
mortality rates. First, these rates may occur simply be-
cause of the lower number of infants with JEB-H in the
AEBR,making a precise interpretation of infant mortality
difficult. Second, these ratesmay occur because, as we ob-
served, someAustralasian families haddecided against pur-
suing surgical interventions: parents’ wishes for nonag-
gressive management were documented in 2 cases after
discussions on prognosis. Althoughmost Australasian in-
fants with JEB-H displayed tracheolaryngeal involve-
ment, ultimately only 1 received a tracheostomy, com-
pared with 24.4% in the United States.14
Our study did not suggest either tracheostomy or gas-
trostomycontributes to long-term survival.One infant (pa-
tient 5) underwent tracheostomy and gastrostomy feed-
ing at 3 and 5 months, respectively, but nevertheless
declined nutritionally and died of gastrointestinal hem-
orrhage at 5.8 months. Two other infants (patients 9 and
10) received gastrostomy feeding at 5 and 8 months, re-
spectively, but died3 to 4months later. Although it is prob-
able that these infants benefited from surgical interven-
tions in the short term, they eventually succumbed to other
complications of their disease.
In relation to the early detection of JEB-H disease, an
indicator in the AEBR cohort was the presence of nail in-
volvement incombinationwithgeneralizedblisteringwithin
days of birth. Its specificity for JEB-H is difficult to ascer-
tain, given that other subtypes of EB have been recorded
with nail abnormalities later in life2; however, the pres-
ence of this finding within the first day of life may provide
an early sign to physicians that a neonate may be affected
with JEB-H.
With regard to supportive care of infants with JEB-H,
attention should be given to avoiding unnecessary physi-
cal trauma during daily care and handling. The disease
course in JEB-H is based largely on the recurrent deepi-
thelization of the skin, resulting in recurrent infections,
chronicblood loss, increasednutritional demands, and sup-
pressed appetite, all of which contribute to potential sep-
sis, anemia, malabsorption, and failure to thrive. Theme-
chanical fragility of these infants is emphasized by the high
numberof erosions foundover thediaper area,which likely
arose from regular diaper changes and friction against the
diaper fabric. Excessive handling of these infants should
beminimized, with nonstick, silicone-based bandages ap-
plied to existing erosions. Dressings with absorbent back-
ings, held in placewith outer dressings, provide some pro-
tection against physical trauma by cushioning the forces
sustained and reducingmaceration of the skin. A high rate
of intraoral blistering has also been observed, which can
further contribute to poor feeding; however, this factor is
more difficult to address.
Last, there are several things to note when interpret-
ing the results from our JEB-H cohort. The small cohort
size limits an accurate reporting of true complication rates;
however, the study’s retrospective nature suggests that
reported rates are likely to be conservative in nature. Un-
derreporting of complications has likely occurred for sev-
eral reasons. First, medical records outside New South
Wales are less accessible, resulting often in incomplete
documentation. Second, records accessed had some vari-
ability in their quality, depending on the degree of docu-
mentation and the physician’s familiarity with EB. Third,
this study was reliant on all manifestations being recog-
nized and recordedduring all clinical presentations,which
was not likely to have occurred. Despite the limited num-
ber of infants with JEB-H, the Australasian cohort re-
mains one of the largest JEB-H case series ever reported
to date and provides a wealth of clinical data regarding
the complications, disease course, and life expectancy of
this rare skin disorder.
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Archives Web Quiz Winner
C ongratulations to the winner of our March quiz,Vijay Zawar, MD, DNB, DVD, consultant derma-
tologist, Nashik, India. The correct answer to ourMarch
challenge was lichen planus pemphigoides (LPP). For a
complete discussion of this case, see the Off-Center Fold
section in the April Archives (Ramaswamy PV, Clark T,
Wilkel C, ZhouL. Bullae, scaly papules, and plaques.Arch
Dermatol. 2010;146[4]:439-444).
Be sure to visit the Archives of DermatologyWeb site
(http://www.archdermatol.com) to try your hand at the
interactive quiz. We invite visitors to make a diagnosis
based on selected information from a case report or other
feature scheduled to be published in the followingmonth’s
print edition of the Archives. The first visitor to e-mail
our Web editors with the correct answer will be recog-
nized in the print journal and on our Web site and will
also receive a free copy of The Art of JAMA II.
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